STAT+: Freenome, high-profile liquid biopsy company, quietly replaces its CEO

Freenome, a high-profile startup that aims to develop a blood test to detect colon cancer, has quietly replaced its co-founder and chief executive, Gabriel Otte.

The company’s chief business officer, Mike Nolan, a long-time veteran of the genomics and diagnostic industries, is Freenome’s new CEO. He was identified as such in a Freenome press release on Friday about new data on its experimental test; he is also listed as CEO on Freenome’s website and on his own LinkedIn profile.

Continue to STAT+ to read the full story…

STAT+: Freenome, high-profile liquid biopsy company, quietly replaces its CEO

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top